our Premium Content: News alerts, weekly reports and conference planners

GENE:

RUNX1 (RUNX Family Transcription Factor 1)

News alerts, weekly reports and conference planners

The role of RAS mutations in leukemia progression, differentiation, and drug resistance. (PubMed, Leuk Res Rep)

Ultimately, RAS mutations drive monocytic differentiation of LSCs and venetoclax (VEN) resistance through BCL-2 family rewiring. Beyond AML, they are hallmark genetic lesions in juvenile myelomonocytic leukemia (JMML) and present in 15%-20% of pediatric acute lymphoblastic leukemia (ALL) cases. Here, we propose a comprehensive pathogenic model and targeted therapeutic framework focusing on RAS, MCL-1, BCL2L1 to overcome drug resistance and improve patient outcomes.

1 day ago

Review • Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1) • RAS (Rat Sarcoma Virus) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

KRAS mutation • NRAS mutation • FLT3-ITD mutation • KIT mutation • RUNX1 mutation • RAS mutation • MLL rearrangement • MLL mutation

Venclexta (venetoclax)

Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations. (PubMed, Cancer Med)

This study provides clinical evidence for prognosis assessment in PHF6-mutated AML, enabling more precise risk stratification, individualized treatment, and further pathogenesis research.

1 day ago

Retrospective data • Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • RUNX1 (RUNX Family Transcription Factor 1) • PHF6 (PHD Finger Protein 6)

IDH2 mutation • RUNX1 mutation

Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes (clinicaltrials.gov)

P=N/A, N=20, Recruiting, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

7 days ago

Trial completion date • Trial primary completion date

TERT (Telomerase Reverse Transcriptase) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • GATA2 (GATA Binding Protein 2) • ANKRD26 (Ankyrin Repeat Domain Containing 26)

VERDI: Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=29, Recruiting, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | Active, not recruiting --> Recruiting

7 days ago

Enrollment open

ABL1 (ABL proto-oncogene 1) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

NPM1 mutation

Venclexta (venetoclax) • azacitidine

Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance. (PubMed, Leukemia)

RUNX1 disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies RUNX1 alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.

7 days ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)

cytarabine

ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Feb 2027

8 days ago

Trial completion date

ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • CD4 (CD4 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)

Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • mercaptopurine • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)

Frequency of prognostically important acute myeloid leukemia mutations in the Iranian population: A systematic review and meta-analysis. (PubMed, Caspian J Intern Med)

Studies have shown that the FLT3-ITD mutation is the most prevalent mutation among Iranian AML patients. Following this, the most common mutations identified were NPM1, CEBPA, DNMT3A, and WT1, in that order.

8 days ago

Retrospective data • Review • Journal

FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

FLT3-ITD mutation • NPM1 mutation • ASXL1 mutation • FLT3-TKD mutation

10d

Protein-Encoding Chemically Modified mRNAs for Musculoskeletal Tissue Regeneration and Repair. (PubMed, J Funct Biomater)

Alongside these progresses, the advantages and disadvantages of applying chemically modified mRNA for musculoskeletal tissue regeneration are also discussed. While studies show the promise of cmRNA for therapeutic applications in orthopedic tissue regeneration, more research is required to optimize growth factors and delivery methods, as well as validate long-term safety and efficacy prior to successful translation into new therapies to benefit patients.

10 days ago

Review • Journal

RUNX1 (RUNX Family Transcription Factor 1) • VEGFA (Vascular endothelial growth factor A) • IGF1 (Insulin-like growth factor 1) • FGF (Fibroblast Growth Factor)

10d

Cell fusion reprograms tumor cells and promotes RUNX1-mediated invasion and dissemination in colorectal cancer. (PubMed, bioRxiv)

In patients with CRC, RUNX1 + hybrid cells were identified in both primary tumor and peripheral blood, where circulating hybrid cells (CHCs) exhibited enriched migratory and epithelial-to-mesenchymal transition (EMT) phenotypes. Taken together, these findings reveal a mechanistic role for RUNX1 in driving invasive behavior of tumor-immune hybrids and highlight disseminated CHCs as an under-recognized contributor to metastatic spread and a promising noninvasive biomarker for tumor progression.

10 days ago

Journal

RUNX1 (RUNX Family Transcription Factor 1)

13d

Implementing Next-Generation Sequencing (NGS) in Resource-Constrained Settings: The Experience of the International Consortium on Acute Leukemias (ICAL). (PubMed, Clin Lymphoma Myeloma Leuk)

Mutation frequencies were consistent with those reported in European and North American cohorts. The present study demonstrates that simplified NGS workflows can be successfully established and quality-controlled in resource-constrained settings through international collaboration, training, and standardized protocols.

13 days ago

Review • Journal • Next-generation sequencing

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)

FLT3-ITD mutation • ASXL1 mutation